Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash & Equivalents (2016 - 2025)

Aptevo Therapeutics' Cash & Equivalents history spans 11 years, with the latest figure at $3.2 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 58.38% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $3.2 million, down 58.38%, while the annual FY2024 figure was $1.2 million, 93.01% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $3.2 million at Aptevo Therapeutics, down from $8.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $61.7 million in Q2 2021 and bottomed at $1.2 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $17.0 million (2023), against an average of $22.6 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 711.33% in 2021 before it plummeted 93.01% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $46.3 million in 2021, then crashed by 53.42% to $21.6 million in 2022, then fell by 21.63% to $16.9 million in 2023, then tumbled by 93.01% to $1.2 million in 2024, then skyrocketed by 173.24% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Cash & Equivalents are $3.2 million (Q3 2025), $8.1 million (Q2 2025), and $1.3 million (Q1 2025).